Charles Schwab
TXG icon

Charles Schwab’s 10x Genomics TXG Stock Holding History

Charles Schwab’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.7M Sell
1,087,150
-39,906
-4% -$1.05M 0.01% 1379
2026
Q1 		$23.9M Buy
1,127,056
+20,734
+2% +$414K ﹤0.01% 1638
2025
Q4 		$18M Sell
1,106,322
-38,866
-3% -$587K ﹤0.01% 1816
2025
Q3 		$13.4M Buy
1,145,188
+240,851
+27% +$3.14M ﹤0.01% 1964
2025
Q2 		$10.5M Buy
904,337
+255,927
+39% +$2.33M ﹤0.01% 1989
2025
Q1 		$5.66M Buy
648,410
+108,744
+20% +$1.37M ﹤0.01% 2217
2024
Q4 		$7.75M Sell
539,666
-111,916
-17% -$1.77M ﹤0.01% 2130
2024
Q3 		$14.7M Sell
651,582
-313,100
-32% -$6.47M ﹤0.01% 1858
2024
Q2 		$18.8M Buy
964,682
+20,325
+2% +$532K ﹤0.01% 1718
2024
Q1 		$35.4M Buy
944,357
+19,525
+2% +$858K 0.01% 1243
2023
Q4 		$51.8M Buy
924,832
+32,709
+4% +$1.42M 0.01% 955
2023
Q3 		$36.8M Buy
892,123
+113,651
+15% +$5.91M 0.01% 1102
2023
Q2 		$43.5M Buy
778,472
+19,425
+3% +$1.05M 0.01% 949
2023
Q1 		$42.3M Sell
759,047
-2,589
-0.3% -$121K 0.01% 951
2022
Q4 		$27.8M Buy
761,636
+30,002
+4% +$981K 0.01% 1197
2022
Q3 		$20.8M Buy
731,634
+205,870
+39% +$7.84M 0.01% 1354
2022
Q2 		$23.8M Buy
525,764
+23,494
+5% +$1.22M 0.01% 1269
2022
Q1 		$38.2M Buy
502,270
+10,014
+2% +$876K 0.01% 1059
2021
Q4 		$73.3M Buy
492,256
+17,092
+4% +$2.62M 0.02% 681
2021
Q3 		$69.2M Sell
475,164
-75,925
-14% -$13M 0.02% 674
2021
Q2 		$108M Buy
551,089
+22,515
+4% +$4.07M 0.04% 461
2021
Q1 		$95.7M Buy
528,574
+70,889
+15% +$12.2M 0.04% 473
2020
Q4 		$64.8M Buy
457,685
+28,922
+7% +$4.2M 0.03% 632
2020
Q3 		$53.5M Buy
428,763
+371,470
+648% +$39M 0.02% 635
2020
Q2 		$5.12M Buy
57,293
+9,992
+21% +$778K ﹤0.01% 2019
2020
Q1 		$2.95M Buy
47,301
+1,050
+2% +$81.9K ﹤0.01% 2097
2019
Q4 		$3.53M Buy
+46,251
New +$2.78M ﹤0.01% 2208

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Charles Schwab's TXG Position: Q2 2026 in Review

Charles Schwab reduced its 10x Genomics (TXG) stake by 3.5% in Q2 2026, selling an estimated $1.05M and leaving 1,087,150 shares worth $41.7M. The position accounts for 0.01% of the portfolio, ranked #1379.

Charles Schwab first reported a position in TXG in Q4 2019 and has held it in 27 quarters since. The position peaked at $108M in Q2 2021. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Charles Schwab held 1,087,150 shares of 10x Genomics worth $41.7M as of Q2 2026.
  • Charles Schwab sold 39,906 10x Genomics shares in Q2 2026, an estimated $1.05M.
  • 10x Genomics made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1379 holding.
  • Charles Schwab first reported a position in 10x Genomics in Q4 2019 and has held it in 27 quarters since.
  • Charles Schwab's 10x Genomics position peaked at $108M in Q2 2021.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.